Show simple item record

dc.contributor.authorClemons, NJ
dc.contributor.authorLiu, DS
dc.contributor.authorDuong, CP
dc.contributor.authorPhillips, WA
dc.date.accessioned2020-12-21T03:59:23Z
dc.date.available2020-12-21T03:59:23Z
dc.date.issued2017-01-01
dc.identifierpii: 1344757
dc.identifier.citationClemons, N. J., Liu, D. S., Duong, C. P. & Phillips, W. A. (2017). Inhibiting system x(C)(-) and glutathione biosynthesis - a potential Achilles' heel in mutant-p53 cancers. MOLECULAR & CELLULAR ONCOLOGY, 4 (5), https://doi.org/10.1080/23723556.2017.1344757.
dc.identifier.issn2372-3556
dc.identifier.urihttp://hdl.handle.net/11343/257441
dc.description.abstractEffective therapeutic strategies to target mutant tumor protein p53 (TP53, best known as p53) cancers remain an unmet medical need. We found that mutant p53 impairs the function of nuclear factor (erythroid-derived 2)-like 2 (NFE2L2, commonly known as NRF2), suppresses solute carrier family 7 member 11 (SLC7A11) expression, and diminishes cellular glutamate/cystine exchange. This decreases glutathione biosynthesis, resulting in redox imbalance. Mutant p53 tumors are thus inherently susceptible to further perturbations of the SLC7A11/glutathione axis.
dc.languageEnglish
dc.publisherTAYLOR & FRANCIS INC
dc.titleInhibiting system x(C)(-) and glutathione biosynthesis - a potential Achilles' heel in mutant-p53 cancers
dc.typeJournal Article
dc.identifier.doi10.1080/23723556.2017.1344757
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.affiliation.departmentSurgery (St Vincent's)
melbourne.source.titleMolecular & cellular oncology
melbourne.source.volume4
melbourne.source.issue5
melbourne.identifier.nhmrc1120293
dc.rights.licenseCC BY-NC-ND
melbourne.elementsid1270191
melbourne.contributor.authorDuong, Cuong
melbourne.contributor.authorClemons, Nicholas
melbourne.contributor.authorPhillips, Wayne
dc.identifier.eissn2372-3548
melbourne.identifier.fundernameidQUEENSLAND INSTITUTE OF MEDICAL RESEARCH, 1040947
melbourne.identifier.fundernameidNHMRC, 1120293
melbourne.identifier.fundernameidVIC CANCER AGENCY, TRP15012
melbourne.identifier.fundernameidVIC CANCER AGENCY, MCRF16002
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record